Search

Cytokinetics Inc

Closed

SectorHealthcare

67.59 0.06

Overview

Share price change

24h

Current

Min

67.28

Max

69

Key metrics

By Trading Economics

Income

7.3M

-199M

Sales

13M

32M

EPS

-1.5

Profit margin

-622.805

Employees

673

EBITDA

-22M

-192M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+64.85% upside

Dividends

By Acuity

Next Earnings

4 Nov 2026

Market Stats

By TradingEconomics

Market Cap

-307M

10B

Previous open

67.53

Previous close

67.59

News Sentiment

By Acuity

50%

50%

111 / 339 Healthcare

Cytokinetics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

21 Sept 2026, 19:16 UTC

Cytokinetics Inc shares fell significantly, currently positioned near the lower end of its one-month range and below its 20-day moving average.

19 Sept 2026, 00:02 UTC

Cytokinetics Inc is rising in after-market trading, gaining ground since Friday's close while positioned below its 20-day moving average.

18 Sept 2026, 20:06 UTC

News

Cytokinetics Inc shares fell sharply, reaching their lowest point just before noon and finishing near the lower end of their one-month range.

17 Sept 2026, 19:36 UTC

Cytokinetics Inc is trading slightly higher, having reached a session high earlier before pulling back, while remaining below its 20-day moving average.

16 Sept 2026, 23:16 UTC

Cytokinetics Inc is experiencing a modest decline in after-market trading, reversing from an initial uptick and reaching its lowest point of the day.

15 Sept 2026, 20:01 UTC

Cytokinetics Inc shares are lower as the NY Empire State Manufacturing Index fell sharply, raising concerns about economic contraction in the manufacturing sector.

11 Sept 2026, 20:08 UTC

News
Social Media

Cytokinetics Inc shares are higher as analysts express positive sentiments, with Cantor Fitzgerald reiterating an Overweight rating and a price target of $112 from Truist.

9 Sept 2026, 19:36 UTC

Cytokinetics Inc shares are lower today amid rising crude oil prices and inflation concerns. The stock is currently below its 20-day moving average.

8 Sept 2026, 23:56 UTC

Cytokinetics Inc shares are higher in after-market trading, reflecting broader market sentiment following a strong jobs report and rising interest rate expectations.

4 Sept 2026, 23:51 UTC

Cytokinetics Inc shares are higher in after-market trading, reaching their highest cumulative return of the day, despite no specific news driving the move.

3 Sept 2026, 19:26 UTC

News

Cytokinetics Inc is trading higher as it announces participation in investor conferences and highlights an upcoming Supplemental New Drug Application for aficamten.

2 Sept 2026, 23:16 UTC

News
Correlated Moves

Cytokinetics Inc shares are trading lower after-market following its investor conference announcements, with Ionis Pharmaceuticals' decline possibly impacting sentiment in the sector.

1 Sept 2026, 20:09 UTC

News
Social Media

Cytokinetics Inc shares are higher as Truist and H.C. Wainwright reaffirm Buy ratings, citing positive momentum and potential from recent ESC conference insights.

31 Aug 2026, 23:01 UTC

Cytokinetics Inc shares are lower in after-market trading amid broader market declines. Concerns over potential interest rate hikes may be influencing the downward trend.

28 Aug 2026, 22:01 UTC

Event

Cytokinetics Inc shares are higher after announcing positive Phase 3 trial results for aficamten at the European Society of Cardiology Congress.

26 Aug 2026, 20:08 UTC

Social Media

Cytokinetics shares advance amid social media discussions of a $100 price target, reflecting gains since Tuesday's close despite mixed U.S. market performance.

14 Aug 2026, 19:26 UTC

Social Media

Cytokinetics shares are higher as H.C. Wainwright maintains a Buy rating and Barclays raises its price target to $110 amid strong sales momentum.

13 Aug 2026, 23:21 UTC

Cytokinetics Inc shares are higher in after-market trading, recovering from three consecutive lower sessions, though still below the 20-day moving average.

12 Aug 2026, 19:46 UTC

Cytokinetics Inc shares are lower today, continuing a decline since Tuesday's close. No specific news was identified to explain the movement.

11 Aug 2026, 19:11 UTC

News

Cytokinetics Inc shares declined as CEO Robert I. Blum sold 7,500 shares at $76.76, raising investor concerns about executive confidence in the company.

10 Aug 2026, 19:46 UTC

News
Social Media

Cytokinetics shares rise as Truist upgrades rating and raises price target to $112, while Citizens increases its target to $110 following strong Q2 results.

8 Aug 2026, 00:01 UTC

Cytokinetics Inc shares are higher in after-market trading, recovering from earlier declines. The stock remains below its 20-day moving average.

7 Aug 2026, 22:51 UTC

Cytokinetics shares are rising in after-market trading, recovering from earlier session lows amid positive sentiment in US equities and mixed labor data.

6 Aug 2026, 23:21 UTC

News
Social Media

Cytokinetics reports Q2 2026 net loss of $198.8 million, better than expected. Shares are higher in after-market trading amid positive sentiment.

5 Aug 2026, 20:06 UTC

Cytokinetics Inc shares are higher amid positive market sentiment and easing crude oil prices, despite a shift from recent daily closing trends.

4 Aug 2026, 23:01 UTC

Cytokinetics Inc is higher in after-market trading, gaining since Tuesday's close, though still below its 20-day moving average with no specific news identified.

3 Aug 2026, 19:36 UTC

Cytokinetics Inc shares are lower amid broader market trends influenced by geopolitical developments. Earlier in the session, shares pulled back from a session high.

31 Jul 2026, 20:02 UTC

Event

Cytokinetics Inc is lower today amid a broader decline in the Biotechnology sub-sector, reversing a trend of higher daily closes since Thursday.

30 Jul 2026, 18:46 UTC

Event
News
Social Media

Cytokinetics receives UK marketing authorization for MYQORZO, a treatment for obstructive hypertrophic cardiomyopathy. Shares are trading higher amid positive market sentiment.

29 Jul 2026, 20:41 UTC

Cytokinetics Inc shares are lower in after-market hours, influenced by a broader market decline amid rising crude oil prices and anticipation of the Fed's policy announcement.

Peer Comparison

Price change

Cytokinetics Inc Forecast

Price Target

By TipRanks

64.85% upside

12 Months Forecast

Average 111.375 USD  64.85%

High 146 USD

Low 85 USD

Based on 17 Wall Street analysts offering 12 month price targets forCytokinetics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

17 ratings

16

Buy

1

Hold

0

Sell

Sentiment

By Acuity

111 / 339 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Cytokinetics Inc

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. It develops small molecule drug candidates primarily engineered to impact muscle function and contractility. The company's drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. The company has a strategic alliance with Ji Xing Pharmaceuticals Limited; and a collaboration and license agreement for the development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.